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Abstract Dietary and policy recommendations fre-
quently focus on reducing saturated fatty acid consumption
for improving cardiometabolic health, based largely on
ecologic and animal studies. Recent advances in nutritional
science now allow assessment of critical questions about
health effects of saturated fatty acids (SFA). We reviewed
the evidence from randomized controlled trials (RCTs) of
lipid and non-lipid risk factors, prospective cohort studies
of disease endpoints, and RCTs of disease endpoints for
cardiometabolic effects of SFA consumption in humans,
including whether effects vary depending on speciﬁc SFA
chain-length; on the replacement nutrient; or on disease
outcomes evaluated. Compared with carbohydrate, the
TC:HDL-C ratio is nonsigniﬁcantly affected by consump-
tion of myristic or palmitic acid, is nonsigniﬁcantly
decreased by stearic acid, and is signiﬁcantly decreased by
lauric acid. However, insufﬁcient evidence exists for dif-
ferent chain-length-speciﬁc effects on other risk pathways
or, more importantly, disease endpoints. Based on consis-
tent evidence from human studies, replacing SFA with
polyunsaturated fat modestly lowers coronary heart disease
risk, with *10% risk reduction for a 5% energy substitu-
tion; whereas replacing SFA with carbohydrate has no
beneﬁt and replacing SFA with monounsaturated fat has
uncertain effects. Evidence for the effects of SFA
consumption on vascular function, insulin resistance, dia-
betes, and stroke is mixed, with many studies showing no
clear effects, highlighting a need for further investigation
of these endpoints. Public health emphasis on reducing
SFA consumption without considering the replacement
nutrient or, more importantly, the many other food-based
risk factors for cardiometabolic disease is unlikely to pro-
duce substantial intended beneﬁts.
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Introduction
Reducing the consumption of saturated fatty acids (SFA) is
a pillar of international dietary recommendations to reduce
the risk of cardiovascular disease (CVD) [1–3]. The World
Health Organization and the US Dietary Guidelines rec-
ommend consuming less than 10%E (percentage of total
energy intake) from SFA [4], and the American Heart
Association less than 7%E [3]. The strong focus on SFA as
a risk factor for CVD originated in the 1960s and 1970s
from lines of evidence including ecologic studies across
nations, short-term metabolic trials in generally healthy
adults assessing total cholesterol (TC) and low-density
lipoprotein cholesterol (LDL-C), and animal experiments
that together appeared to provide consistent support that
SFA intake increased the risk of coronary heart disease
(CHD).
However, several critical questions have remained about
the relationship between SFA consumption and CVD risk.
First, do health effects of reducing SFA consumption vary
depending on whether the replacement nutrient is carbo-
hydrate (CHO), monounsaturated fat (MUFA), or polyun-
saturated fat (PUFA)? A historical emphasis on low fat
diets has produced drops in SFA consumption in the US
and many other nations, but with concomitant increases in
CHO, rather than MUFA or PUFA, as the replacement
nutrient [1]. Is there strong evidence to support this dietary
strategy? Second, do health effects of SFA vary depending
on the chain-length, i.e. comparing 12-, 14-, 16-, and 18-
carbon SFA? Current dietary recommendations generally
focus on overall SFA consumption, without strong atten-
tion on speciﬁc SFA. Third, what is the relationship
between SFA consumption and risk of stroke and type 2
diabetes mellitus? Historically, research on SFA has
focused largely on CHD.
Advances in nutritional science in the last two decades
now provide a substantial body of evidence to answer these
questions (Fig. 1). These include well-conducted random-
ized controlled trials (RCTs) of SFA nutrient substitutions
and multiple risk pathways as endpoints, including multiple
lipid and also non-lipid risk factors (rather than only TC
and LDL-C); and large prospective cohort studies and
meta-analyses of RCTs of SFA consumption and clinical
disease endpoints, that provide more direct evidence for
effects on disease compared with changes in risk factors
alone. Given the complementary strengths and limitations
of these newer research paradigms, conclusions can be
considered most robust when studies from each paradigm
provide concordant evidence for health effects of SFA
consumption. Together these research advances provide
much stronger evidence for causal inference than data from
prior available ecologic studies, limited metabolic studies,
and animal experiments.
To elucidate the effects of SFA consumption on CVD
risk based on the most current evidence, we reviewed the
data from RCTs of multiple risk factors, large prospective
cohort studies of disease endpoints, and RCTs of disease
endpoints. When sufﬁcient evidence was available, we
particularly focused on the potentially different health
effects of varying the replacement nutrient; of different
chain-length SFA; and of speciﬁc effects on CHD, stroke,
and diabetes.
Methods
Two investigators independently reviewed the literature for
English-language articles published through Sep 2009 by
performing searches of Medline, hand-searching of citation
lists, and direct contact with experts. Inclusion criteria were
any RCT or observational study in adults evaluating SFA
consumption and the risk of CHD, stroke, or type 2 dia-
betes and related risk pathways, including lipids and lipo-
proteins, systemic inﬂammation, vascular function, and
Randomized Trials
of Disease Outcomes
Animal Studies
Prospective Cohorts
of Disease Outcomes
Randomized Trials of 
Physiologic Measures / 
Risk Factors
Retrospective Case-Control 
Studies of Disease Outcomes
Ecologic Studies Prevalence Studies
Strength of Evidence
Case Series/ Case Reports
Fig. 1 Advances in nutritional science research paradigms. For
causal inference about how dietary habits affect chronic disease, the
best evidence is derived from randomized controlled trials (RCTs) of
multiple risk pathways, observed differences in disease endpoints in
prospective cohort studies, and effects on disease endpoints in RCTs.
Conclusions can be considered most robust when these complemen-
tary lines of evidence provide concordant results. Adapted with
permission from Harris, Mozaffarian, et al. 2009 [90]
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123insulin resistance (1,254 identiﬁed articles). Search terms
included ‘‘saturated fat(s)’’, ‘‘lipoproteins’’, ‘‘inﬂamma-
tion’’, ‘‘blood pressure’’, ‘‘vascular function’’, ‘‘insulin
resistance’’, ‘‘cardiovascular diseases’’, and ‘‘diabetes
mellitus’’. We focused on identifying RCTs of major risk
factors, large prospective cohort studies of disease end-
points, and RCTs of disease endpoints, given strengths of
these designs and their complementary limitations. We
excluded a priori animal experiments, ecological studies,
commentaries, general reviews, and case reports. Studies
were independently considered by the two investigators for
inclusion; rare differences were resolved by consensus.
Effects on Cardiovascular Risk Factors
Lipids and Lipoproteins
RCTs have established clear multiple effects of SFA con-
sumption on circulating lipids and lipoproteins [5, 6]. Each
of these effects varies depending on the comparison
nutrient, i.e., the nutrient isocalorically replaced for SFA
(Fig. 2). Compared with CHO, SFA intake raises TC and
LDL-C, but also lowers triglycerides and raises high-den-
sity lipoprotein cholesterol (HDL-C). Given these
conﬂicting directions of effects, effects on apolipoproteins
or, even better, a more global risk marker such as the
TC:HDL-C ratio may provide the best overall indication of
potential effects on CHD risk. Compared with CHO, SFA
intake has no signiﬁcant effects on the TC:HDL-C ratio or
ApoB levels, and raises ApoA1 levels. In contrast, con-
sumption of PUFA or MUFA in place of SFA leads to
lowering of TC, LDL-C, and ApoB; slight lowering (for
PUFA) of HDL-C and ApoA1; little effect on triglycerides;
and lowering of the TC:HDL-C ratio. Compared with trans
fatty acids (TFA), SFA intake has minimal effects on LDL-
C but raises HDL-C and lowers triglycerides and lipopro-
tein(a), with improvement in the TC:HDL-C ratio [7].
Thus, consideration of which nutrient is being replaced is
essential when considering lipid effects or designing die-
tary guidelines or policy measures related to SFA con-
sumption. Overall, the changes in lipid and apolipoprotein
levels predict minimal effects on CHD risk when CHO
replaces SFA, beneﬁts when PUFA or MUFA replace SFA,
and harms when TFA replace SFA.
Effects of SFA consumption on serum lipids and lipo-
proteins further vary according to which speciﬁc SFA is
consumed (Fig. 3)[ 5]. With CHO consumption as the
reference, lauric (12:0), myristic (14:0), and palmitic (16:0)
acid raise TC and LDL-C, whereas stearic acid (18:0) does
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Fig. 2 Changes in blood lipid levels for consumption of saturated
fatty acids (SFA), monounsaturated fatty acids (MUFA), polyunsat-
urated fatty acids (PUFA), or trans fatty acids (TFA) as an isocaloric
replacement for carbohydrate (CHO) as a reference, based on two
meta-analyses of randomized controlled feeding trials [5, 6]. b reﬂects
the change for each 1% energy isocaloric replacement; *P\0.05
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123not. All SFA raise HDL-C, but HDL-raising effects are
greater as chain-length decreases. Overall, the TC:HDL-C
ratio is not signiﬁcantly affected by myristic or palmitic
acid consumption, is nonsigniﬁcantly decreased by stearic
acid consumption, and is signiﬁcantly decreased by lauric
acid consumption (Fig. 3). These effects suggest little CHD
beneﬁt of replacing myristic, palmitic, or stearic acid with
CHO, and potential harm of replacing lauric acid with
CHO.
Systemic Inﬂammation
Inﬂammation independently increases risk of CVD and
diabetes [8–11]. Compared with lipid effects, the inﬂuence
of SFA consumption on inﬂammation is less well investi-
gated, with mixed results. In a randomized cross-over trial,
20 healthy men consumed a high SFA (22%E SFA), a high
MUFA (24%E MUFA), and a high CHO high PUFA
(55%E CHO, 8%E PUFA) diet for 4 weeks [12]. At the
end of each intervention period, participants were given a
fat-rich breakfast (60%E fat) with similar fat composition
to that of each diet. Consumption of a butter-rich breakfast
(35%E SFA) had no effect on postprandial plasma levels of
tumor necrosis factor (TNF)-a, interleukin (IL)-6 or
monocyte chemoattractant protein (MCP)-1, compared
with an olive oil-rich breakfast (36%E MUFA) or a walnut-
rich breakfast (16%E PUFA) [12]. In another cross-over
trial of 50 healthy men, consumption of low-chain SFA
(12:0–16:0) for 5 weeks (8%E) had no effect on ﬁbrinogen,
C-reactive protein (CRP), or IL-6 levels; similar con-
sumption of stearic acid (18:0) increased plasma levels of
ﬁbrinogen, but not of CRP or IL-6, compared with CHO
[13]. Among hypercholesterolemic subjects (n = 18), a
one-month diet with 16.7%E from SFA (butter), compared
with 12.5%E from PUFA (soybean oil), resulted in a trend
toward higher macrophage production of TNF-a, without
effects on IL-6 [14].
Observational studies investigating associations between
SFA intake and markers of inﬂammation are limited [15,
16]. Among 4,900 US adults, dietary SFA intake was not
cross-sectionally associated with CRP levels, after adjust-
ing for other risk factors and lifestyle behaviors [15]. Other
cross-sectional studies have been very small and/or not
multivariable-adjusted [16]. Observational studies of cir-
culating (e.g., plasma) or tissue (e.g., adipose) SFA levels
[17, 18] are helpful for investigating effects of metabolism
but not of SFA consumption, as circulating and tissue SFA
are poorly reﬂective of dietary SFA due to endogenous
synthesis and regulation by lipolysis, lipogenesis, and beta-
oxidation [19–22]. Overall, the limited and mixed evidence
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Fig. 3 Changes in blood lipid levels for consumption of different
chain-length saturated fatty acids (SFA) as an isocaloric replacement
for carbohydrate (CHO), based on meta-analysis of randomized
controlled feeding trials [5]. b reﬂects the change for each 1% energy
isocaloric replacement; *P\0.05
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123precludes strong conclusions about potential pro-inﬂam-
matory effects of SFA consumption.
Blood Pressure, Endothelial Function, and Arterial
Stiffness
Effects of dietary SFA on markers of vascular function
including blood pressure, endothelial function, and arterial
stiffness are similarly not well characterized [23]. A few
observational studies have evaluated SFA intake and inci-
dence of hypertension, with mixed results [24, 25]. Among
30,681 US men followed for 4 years, no signiﬁcant asso-
ciations were seen between SFA intake and incident
hypertension, after adjusting for age, body mass index, and
alcohol consumption [24]. In contrast, among 11,342 US
men in the MRFIT study, SFA intake was cross-sectionally
positively associated with systolic and diastolic blood
pressure, after adjusting for risk factors and lifestyle
behaviors, although no adjustments were made for other
dietary fats, CHO, or protein [25].
Randomized controlled feeding trials ranging in dura-
tion from 3 weeks to 6 months have demonstrated mixed
results of SFA intake compared with MUFA, PUFA, TFA,
or CHO on measures of blood pressure, endothelial dys-
function, and/or arterial stiffness [23] (Table 1). Among
nine trials assessing blood pressure, seven observed no
differences between the different diets [26–34]. These trials
evaluated a range of SFA consumption levels and
replacement nutrients (Table 1). Improvements in BP were
seen in two of ﬁve RCTs including a comparison to
Table 1 Effects of saturated fatty acids on blood pressure, endothelial function, and arterial stiffness in human feeding trials
Study Outcome N Duration Design Comparison SFA replaced by
PUFA MUFA TFA CHO
Margetts
et al. [26]
Blood pressure 54 6 weeks Cross-over 18%E SFA versus 15%E PUFA $
Puska et al.
[27]
Blood pressure 84 12 weeks Parallel 11%E SFA versus 8%E PUFA $
Sacks et al.
[28]
Blood pressure 21 6 weeks Cross-over 16%E SFA versus 14%E PUFA or
52%E CHO
$$
Storm et al.
[29]
Blood pressure 15 3 weeks Cross-over 13%E 18:0 SFA versus 16%E 16:0 SFA
or 51%E CHO
$
Piers et al.
[30]
Blood pressure 8 4 weeks Cross-over 24%E SFA versus 23%E MUFA $
Sanders et al.
[31]
Blood pressure 110 6 months Parallel 17%E SFA versus 17%E MUFA or
CHO
a
$$
Uusitupa
et al. [33]
Blood pressure 159 6 months Parallel 14%E SFA vs. 8%E PUFA, 11%E
MUFA, or 53%E CHO
$$ $
Lahoz et al.
[32]
Blood pressure 42 5 weeks Consecutive diets-
non randomized
17%E SFA versus 21%E MUFA or
13%E PUFA
;;
Rasmussen
et al. [34]
Blood pressure 162 3 months Parallel 18%E SFA versus 21%E MUFA ;
de Roos et al.
[35]
Endothelial
function – FMD
29 4 weeks Cross-over 23%E SFA versus 9%E TFA ;
Fuentes et al.
[36]
Endothelial
function – FMD
22 4 weeks Cross-over 20%E SFA versus 22%E MUFA or
57%E CHO
: $
Keogh et al.
[37]
Endothelial
function – FMD
40 3 weeks Cross-over 19%E SFA versus 19%E MUFA, 10%E
PUFA, or 65%E CHO
:: :
Sanders et al.
[31]
Endothelial
function – FMD
110 6 months Parallel 17%E SFA versus 17%E MUFA or
CHO
a
$$
Keogh et al.
[37]
Arterial stiffness
– PWV
40 3 weeks Cross-over 19%E SFA versus 19%E MUFA, 10%E
PUFA, or 65%E CHO
$$ $
Sanders et al.
[31]
Arterial stiffness
– PWV
110 6 months Parallel 17%E SFA versus 17%E MUFA or
CHO
a
$$
Direction of effect on reported outcome (: increased; ; decreased; $ no effect)
CHO carbohydrate, MUFA monounsaturated fatty acids, FMD brachial artery ﬂow-mediated dilatation, PUFA polyunsaturated fatty acids, PWV
pulse wave velocity, SFA saturated fatty acids, TFA trans fatty acids, %E percentage of total energy intake
a %E not reported
Lipids (2010) 45:893–905 897
123MUFA, one of ﬁve RCTs including a comparison to PUFA,
and zero of four RCTs including a comparison to CHO.
Among four trials assessing indices of endothelial function,
three observed differences in brachial artery ﬂow-mediated
dilatation (FMD) between the different diets [31, 35–37].
Improvements in endothelial function were seen in two of
three RCTs including a comparison to MUFA, one RCT
including a comparison to PUFA, and one of three RCTs
including a comparison to CHO; endothelial function was
worsened in one RCT replacing SFA with TFA. In two
trials evaluating arterial stiffness as assessed by pulse wave
velocity (PWV) [31, 37], no effects of reducing SFA
consumption were seen, including two RCTs including a
comparison to MUFA, one RCT including a comparison to
PUFA, and two RCTs including a comparison to CHO.
Thus, evidence for effects of SFA consumption on vascular
function is mixed, with no clear pattern based on under-
lying population characteristics, SFA consumption levels,
or the comparison nutrient, and with most studies sug-
gesting no effects.
Insulin Resistance and Diabetes
SFA has been considered a risk factor for insulin resistance
and diabetes mellitus [38], but review of the current evi-
dence indicates surprisingly equivocal ﬁndings. SFA con-
sumption inconsistently affects insulin resistance in
controlled trials (Table 2) and has not been associated with
incident diabetes in prospective cohort studies (Fig. 4)[ 39–
52]. Among generally healthy individuals, most RCTs
show no differences in markers of glucose-insulin
homeostasis comparing different intakes of SFA versus
MUFA, PUFA, or CHO. Findings are more mixed among
individuals having or predisposed to insulin resistance. In
these individuals, improvements in markers of glucose-
insulin homeostasis were seen in three of ﬁve RCTs
including a comparison to MUFA, one of three RCTs
including a comparison to PUFA, and one RCT including a
comparison to CHO. Among all these trials, the great
majority were short-term (up to several weeks) and sur-
prisingly small (\20 subjects). The two largest trials
(n = 162, n = 59) found SFA to worsen several indices of
glucose-insulin homeostasis in comparison to MUFA (two
trials) or CHO (one trial).
Signiﬁcant additional insight into effects of dietary fats
on glucose-insulin homeostasis can be gained from long-
term studies evaluating actual onset of diabetes. Among
four large prospective cohort studies, none found inde-
pendent associations between consumption of either SFA
(Fig. 4) or MUFA and onset of diabetes [53–56]. In con-
trast, three of four cohorts [54] observed lower incidence of
diabetes with greater consumption of PUFA and/or vege-
table fat [53, 55, 56]. In the large Women’s Health
Initiative trial (n = 45,887), SFA intake was reduced in the
intervention group from 12.7 to 9.5%E over 8 years as part
of overall total fat reduction, largely replaced with CHO
[57]. In this large RCT, this signiﬁcant reduction in SFA
consumption had no effect on fasting glucose, fasting
insulin, homeostasis model assessment (HOMA) insulin
resistance, or incident diabetes (RR = 0.95, 95%
CI = 0.90–1.03).
Thus, some evidence from short-term RCTs suggests
that SFA consumption in place of MUFA may worsen
glucose-insulin homeostasis, especially among individuals
predisposed to insulin resistance. However, several long-
term observational studies and one large RCT suggest no
effect of SFA consumption on onset of diabetes. Further
conﬁrmatory results of either harm or no effect in addi-
tional appropriately powered studies are needed given the
present inconsistency of effects across all studies.
Weight Gain and Adiposity
The role of total dietary fat in obesity has been widely
studied due to its high energy content (9 kcal/g) and sub-
sequent potential for weight gain [58–60]. Based on RCTs
of weight loss with balanced-intensity interventions (i.e.,
all individuals receiving similar guidance and follow-up,
with only the speciﬁc dietary advice varying) and pro-
spective observational studies of weight gain, the %E from
total fat does not have strong effects on adiposity compared
with overall quality and quantity of foods consumed.
Evidence for independent effects of speciﬁc dietary fats
such as SFA on weight gain or adiposity are much more
limited. In two large prospective cohort studies, increases
in SFA consumption were associated with very small
increases in abdominal circumference [61] or body weight
during 8–9 years follow-up [62] compared with CHO, after
adjusting for other risk factors and lifestyle and dietary
behaviors.
Relationships with Cardiovascular Events
Coronary Heart Disease—Prospective Cohort Studies
Most individual prospective cohort studies have not
observed an independent relationship between SFA con-
sumption and incident CHD [63–67]. The relatively small
number of published studies, among the many available
international cohorts, also raises concern for potential
publication bias (i.e., additional unreported null studies).
Two recent systematic reviews and meta-analyses, the ﬁrst
including 9 cohorts (11 estimates) evaluating 160,673
individuals [64], and the second including 16 cohorts
among 214,182 individuals [68], found no signiﬁcant
898 Lipids (2010) 45:893–905
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e
c
t
s
o
n
p
o
s
t
p
r
a
n
d
i
a
l
i
n
s
u
l
i
n
a
n
d
C
-
p
e
p
t
i
d
e
N
o
s
i
g
n
i
ﬁ
c
a
n
t
e
f
f
e
c
t
s
o
n
f
a
s
t
i
n
g
i
n
s
u
l
i
n
,
f
a
s
t
i
n
g
C
-
p
e
p
t
i
d
e
,
o
r
f
a
s
t
i
n
g
a
n
d
p
o
s
t
p
r
a
n
d
i
a
l
g
l
u
c
o
s
e
w
i
t
h
a
n
y
d
i
e
t
;
$
V
e
s
s
b
y
e
t
a
l
.
[
4
3
]
M
o
d
e
r
a
t
e
l
y
o
v
e
r
w
e
i
g
h
t
(
B
M
I
2
6
.
5
±
3
k
g
/
m
2
)
,
a
g
e
4
8
.
5
±
7
.
8
y
e
a
r
s
8
6
m
e
n
,
7
6
w
o
m
e
n
3
m
o
n
t
h
s
P
a
r
a
l
l
e
l
T
w
o
i
s
o
c
a
l
o
r
i
c
d
i
e
t
s
:
b
o
t
h
*
3
7
%
E
f
a
t
,
w
i
t
h
1
7
.
6
%
E
S
F
A
,
o
r
2
1
.
2
%
E
M
U
F
A
;
e
a
c
h
g
r
o
u
p
w
a
s
f
u
r
t
h
e
r
r
a
n
d
o
m
i
z
e
d
t
o
3
.
6
g
o
f
e
i
t
h
e
r
o
m
e
g
a
-
3
f
a
t
t
y
a
c
i
d
s
o
r
o
l
i
v
e
o
i
l
S
F
A
v
e
r
s
u
s
M
U
F
A
:
;
i
n
s
u
l
i
n
s
e
n
s
i
t
i
v
i
t
y
b
y
2
3
.
8
%
(
P
=
0
.
0
5
)
,
a
n
d
:
i
n
s
u
l
i
n
l
e
v
e
l
s
b
y
3
0
.
3
%
(
P
=
0
.
0
6
)
d
u
r
i
n
g
a
F
S
I
G
T
T
N
o
s
i
g
n
i
ﬁ
c
a
n
t
e
f
f
e
c
t
s
o
n
a
c
u
t
e
i
n
s
u
l
i
n
r
e
s
p
o
n
s
e
,
o
r
g
l
u
c
o
s
e
l
e
v
e
l
s
d
u
r
i
n
g
a
F
S
I
G
T
T
w
i
t
h
e
i
t
h
e
r
d
i
e
t
;
S
u
m
m
e
r
s
e
t
a
l
.
[
4
4
]
O
b
e
s
e
(
B
M
I
3
7
±
6
k
g
/
m
2
)
,
t
y
p
e
2
d
i
a
b
e
t
i
c
,
a
g
e
5
3
.
7
±
1
1
y
e
a
r
s
E
i
g
h
t
m
e
n
;
n
i
n
e
w
o
m
e
n
5
w
e
e
k
s
C
r
o
s
s
-
o
v
e
r
T
w
o
d
i
e
t
s
:
4
2
%
E
f
a
t
i
n
S
F
A
d
i
e
t
w
i
t
h
2
1
%
E
f
r
o
m
S
F
A
,
a
n
d
3
4
%
E
f
a
t
i
n
P
U
F
A
d
i
e
t
w
i
t
h
9
%
E
f
r
o
m
P
U
F
A
S
F
A
v
e
r
s
u
s
P
U
F
A
:
;
i
n
s
u
l
i
n
s
e
n
s
i
t
i
v
i
t
y
b
y
2
0
.
3
%
(
P
=
0
.
0
2
)
d
u
r
i
n
g
a
n
e
u
g
l
y
c
e
m
i
c
c
l
a
m
p
N
o
s
i
g
n
i
ﬁ
c
a
n
t
e
f
f
e
c
t
s
o
n
f
a
s
t
i
n
g
g
l
u
c
o
s
e
i
n
s
u
l
i
n
,
o
r
t
r
i
g
l
y
c
e
r
i
d
e
s
w
i
t
h
e
i
t
h
e
r
d
i
e
t
;
V
e
g
a
-
L
o
p
e
z
e
t
a
l
.
[
4
5
]
H
y
p
e
r
l
i
p
i
d
e
m
i
c
(
L
D
L
-
c
h
o
l
e
s
t
e
r
o
l
C
1
3
0
m
g
/
d
l
)
,
m
o
d
e
r
a
t
e
l
y
o
v
e
r
w
e
i
g
h
t
(
B
M
I
2
6
±
2
.
4
k
g
/
m
2
)
,
a
g
e
6
3
.
9
±
5
.
7
y
e
a
r
s
F
i
v
e
m
e
n
;
t
e
n
w
o
m
e
n
5
w
e
e
k
s
C
r
o
s
s
-
o
v
e
r
F
o
u
r
i
s
o
c
a
l
o
r
i
c
d
i
e
t
s
:
a
l
l
*
3
0
%
E
f
a
t
,
w
i
t
h
2
0
%
E
f
r
o
m
p
a
r
t
i
a
l
l
y
h
y
d
r
o
g
e
n
a
t
e
d
s
o
y
b
e
a
n
(
4
.
2
%
E
T
F
A
)
,
s
o
y
b
e
a
n
(
1
2
.
5
%
E
P
U
F
A
)
,
p
a
l
m
(
1
4
.
8
%
E
S
F
A
)
,
o
r
c
a
n
o
l
a
(
1
5
.
4
%
E
M
U
F
A
)
S
F
A
v
e
r
s
u
s
P
U
F
A
,
M
U
F
A
,
o
r
T
F
A
:
n
o
s
i
g
n
i
ﬁ
c
a
n
t
e
f
f
e
c
t
s
o
n
f
a
s
t
i
n
g
i
n
s
u
l
i
n
,
f
a
s
t
i
n
g
g
l
u
c
o
s
e
,
o
r
H
O
M
A
$
$
$
P
a
n
i
a
g
u
a
e
t
a
l
.
[
4
6
]
O
b
e
s
e
(
B
M
I
3
2
.
6
±
7
.
8
k
g
/
m
2
)
,
i
n
s
u
l
i
n
r
e
s
i
s
t
a
n
t
(
a
s
a
s
s
e
s
s
e
d
b
y
O
G
T
T
)
,
a
g
e
6
2
.
3
±
9
.
4
y
e
a
r
s
F
o
u
r
m
e
n
;
s
e
v
e
n
w
o
m
e
n
2
8
d
a
y
s
C
r
o
s
s
-
o
v
e
r
T
h
r
e
e
i
s
o
c
a
l
o
r
i
c
d
i
e
t
s
:
3
8
%
E
f
a
t
a
n
d
4
7
%
E
C
H
O
i
n
t
h
e
t
w
o
h
i
g
h
-
f
a
t
d
i
e
t
s
,
w
i
t
h
2
3
%
E
f
r
o
m
S
F
A
o
r
M
U
F
A
,
a
n
d
2
0
%
E
f
a
t
a
n
d
6
5
%
E
C
H
O
i
n
t
h
e
l
o
w
-
f
a
t
d
i
e
t
(
t
h
e
l
a
t
t
e
r
a
s
a
r
e
p
l
a
c
e
m
e
n
t
o
f
S
F
A
)
S
F
A
v
e
r
s
u
s
M
U
F
A
:
:
H
B
A
1
c
(
P
\
0
.
0
1
)
,
:
f
a
s
t
i
n
g
g
l
u
c
o
s
e
b
y
9
.
6
%
(
P
\
0
.
0
5
)
,
:
H
O
M
A
b
y
1
7
.
2
%
(
P
\
0
.
0
1
)
,
:
f
a
s
t
i
n
g
p
r
o
i
n
s
u
l
i
n
b
y
2
6
.
1
%
(
P
\
0
.
0
5
)
,
n
o
s
i
g
n
i
ﬁ
c
a
n
t
e
f
f
e
c
t
s
o
n
p
o
s
t
p
r
a
n
d
i
a
l
g
l
u
c
o
s
e
,
p
o
s
t
p
r
a
n
d
i
a
l
i
n
s
u
l
i
n
,
o
r
p
o
s
t
p
r
a
n
d
i
a
l
G
L
P
-
1
S
F
A
v
s
.
C
H
O
:
:
H
B
A
1
c
b
y
6
.
3
%
(
P
\
0
.
0
1
)
,
:
f
a
s
t
i
n
g
g
l
u
c
o
s
e
b
y
9
.
3
%
(
P
\
0
.
0
5
)
,
;
p
o
s
t
p
r
a
n
d
i
a
l
g
l
u
c
o
s
e
b
y
5
1
%
(
P
\
0
.
0
5
)
,
;
p
o
s
t
p
r
a
n
d
i
a
l
i
n
s
u
l
i
n
b
y
5
3
%
(
P
\
0
.
0
5
)
,
:
p
o
s
t
p
r
a
n
d
i
a
l
G
L
P
-
1
b
y
1
3
4
.
6
%
(
P
\
0
.
0
5
)
,
n
o
s
i
g
n
i
ﬁ
c
a
n
t
e
f
f
e
c
t
s
o
n
H
O
M
A
o
r
f
a
s
t
i
n
g
p
r
o
i
n
s
u
l
i
n
N
o
s
i
g
n
i
ﬁ
c
a
n
t
e
f
f
e
c
t
s
o
n
f
a
s
t
i
n
g
i
n
s
u
l
i
n
o
r
G
L
P
-
1
,
o
r
t
h
e
6
0
m
i
n
p
r
o
i
n
s
u
l
i
n
:
i
n
s
u
l
i
n
r
a
t
i
o
w
i
t
h
a
n
y
d
i
e
t
;
;
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a
b
l
e
2
c
o
n
t
i
n
u
e
d
S
t
u
d
y
S
u
b
j
e
c
t
s
N
D
u
r
a
t
i
o
n
D
e
s
i
g
n
C
o
m
p
a
r
i
s
o
n
O
u
t
c
o
m
e
s
a
n
d
r
e
s
u
l
t
s
S
F
A
r
e
p
l
a
c
e
d
b
y
P
U
F
A
M
U
F
A
T
F
A
C
H
O
L
i
t
h
a
n
d
e
r
e
t
a
l
.
[
4
7
]
H
y
p
e
r
l
i
p
i
d
e
m
i
c
(
L
D
L
3
.
0
–
5
.
0
m
m
o
l
/
L
)
,
m
o
d
e
r
a
t
e
l
y
o
v
e
r
w
e
i
g
h
t
(
B
M
I
2
5
.
9
±
4
.
2
k
g
/
m
2
)
,
a
g
e
3
9
.
7
±
1
3
.
9
y
e
a
r
s
1
8
m
e
n
3
w
e
e
k
s
C
r
o
s
s
-
o
v
e
r
T
w
o
i
s
o
c
a
l
o
r
i
c
d
i
e
t
s
,
b
o
t
h
3
8
%
E
f
a
t
:
1
8
%
E
S
F
A
,
1
0
%
E
M
U
F
A
a
n
d
7
%
E
P
U
F
A
i
n
t
h
e
h
i
g
h
S
F
A
:
U
S
F
A
d
i
e
t
,
a
n
d
1
3
%
E
S
F
A
,
1
2
%
E
M
U
F
A
a
n
d
8
%
E
P
U
F
A
i
n
t
h
e
l
o
w
S
F
A
:
U
S
F
A
d
i
e
t
S
F
A
v
e
r
s
u
s
P
U
F
A
?
M
U
F
A
:
N
o
s
i
g
n
i
ﬁ
c
a
n
t
e
f
f
e
c
t
s
o
n
f
a
s
t
i
n
g
a
d
i
p
o
n
e
c
t
i
n
$
$
H
e
a
l
t
h
y
i
n
d
i
v
i
d
u
a
l
s
S
c
h
w
a
b
e
t
a
l
.
[
4
8
]
H
e
a
l
t
h
y
,
n
o
r
m
a
l
w
e
i
g
h
t
(
B
M
I
2
1
.
4
±
0
.
5
k
g
/
m
2
)
,
a
g
e
2
3
.
9
±
1
.
2
y
e
a
r
s
1
1
w
o
m
e
n
4
w
e
e
k
s
C
r
o
s
s
-
o
v
e
r
T
w
o
i
s
o
c
a
l
o
r
i
c
d
i
e
t
s
:
a
l
l
*
3
8
%
E
f
a
t
,
w
i
t
h
5
%
E
f
r
o
m
l
a
u
r
i
c
a
c
i
d
(
1
2
:
0
S
F
A
)
,
o
r
1
1
.
4
%
E
f
r
o
m
p
a
l
m
i
t
i
c
a
c
i
d
(
1
6
:
0
S
F
A
)
1
2
:
0
S
F
A
v
e
r
s
u
s
1
6
:
0
S
F
A
:
n
o
s
i
g
n
i
ﬁ
c
a
n
t
e
f
f
e
c
t
s
o
n
i
n
s
u
l
i
n
,
g
l
u
c
o
s
e
,
a
c
u
t
e
i
n
s
u
l
i
n
r
e
s
p
o
n
s
e
,
o
r
i
n
s
u
l
i
n
s
e
n
s
i
t
i
v
i
t
y
i
n
d
e
x
d
u
r
i
n
g
a
F
S
I
G
T
T
w
i
t
h
e
i
t
h
e
r
d
i
e
t
F
a
s
c
h
i
n
g
e
t
a
l
.
[
4
9
]
H
e
a
l
t
h
y
,
n
o
r
m
a
l
w
e
i
g
h
t
(
B
M
I
2
2
.
4
±
1
.
8
k
g
/
m
2
)
,
a
g
e
2
6
±
3
.
5
y
e
a
r
s
8
m
e
n
1
w
e
e
k
C
r
o
s
s
-
o
v
e
r
F
o
u
r
i
s
o
c
a
l
o
r
i
c
d
i
e
t
s
:
5
4
%
E
f
a
t
a
n
d
3
5
%
E
C
H
O
i
n
t
h
e
t
h
r
e
e
h
i
g
h
-
f
a
t
d
i
e
t
s
w
i
t
h
3
1
.
5
%
E
f
r
o
m
S
F
A
,
2
8
%
E
f
r
o
m
P
U
F
A
a
n
d
2
2
%
E
f
r
o
m
M
U
F
A
,
a
n
d
2
5
%
E
f
a
t
a
n
d
6
4
%
E
C
H
O
i
n
t
h
e
h
i
g
h
C
H
O
d
i
e
t
S
F
A
v
e
r
s
u
s
P
U
F
A
,
M
U
F
A
,
o
r
C
H
O
:
n
o
s
i
g
n
i
ﬁ
c
a
n
t
e
f
f
e
c
t
s
o
n
i
n
s
u
l
i
n
,
g
l
u
c
o
s
e
,
a
c
u
t
e
i
n
s
u
l
i
n
r
e
s
p
o
n
s
e
,
o
r
i
n
s
u
l
i
n
s
e
n
s
i
t
i
v
i
t
y
i
n
d
e
x
d
u
r
i
n
g
a
F
S
I
G
T
T
w
i
t
h
a
n
y
d
i
e
t
$
$
$
L
o
u
h
e
r
a
n
t
a
e
t
a
l
.
[
5
0
]
H
e
a
l
t
h
y
,
n
o
r
m
a
l
w
e
i
g
h
t
(
B
M
I
2
2
.
6
±
0
.
6
k
g
/
m
2
)
,
a
g
e
2
2
±
0
.
6
y
e
a
r
s
1
4
w
o
m
e
n
4
w
e
e
k
s
C
r
o
s
s
-
o
v
e
r
T
w
o
i
s
o
c
a
l
o
r
i
c
d
i
e
t
s
:
b
o
t
h
*
3
8
%
E
f
a
t
,
w
i
t
h
1
8
.
5
%
E
f
r
o
m
S
F
A
o
r
M
U
F
A
S
F
A
v
e
r
s
u
s
M
U
F
A
:
n
o
s
i
g
n
i
ﬁ
c
a
n
t
e
f
f
e
c
t
s
o
n
i
n
s
u
l
i
n
,
g
l
u
c
o
s
e
,
a
c
u
t
e
i
n
s
u
l
i
n
r
e
s
p
o
n
s
e
,
o
r
i
n
s
u
l
i
n
s
e
n
s
i
t
i
v
i
t
y
i
n
d
e
x
d
u
r
i
n
g
a
F
S
I
G
T
T
w
i
t
h
e
i
t
h
e
r
d
i
e
t
$
P
e
r
e
z
-
J
i
m
e
n
e
z
e
t
a
l
.
[
5
2
]
H
e
a
l
t
h
y
,
n
o
r
m
a
l
w
e
i
g
h
t
(
B
M
I
2
2
.
8
7
±
2
.
4
5
k
g
/
m
2
)
,
a
g
e
2
3
.
1
±
1
.
8
y
e
a
r
s
3
0
m
e
n
,
2
9
w
o
m
e
n
2
8
d
a
y
s
C
r
o
s
s
-
o
v
e
r
B
a
s
e
l
i
n
e
2
8
-
d
a
y
h
i
g
h
S
F
A
d
i
e
t
f
o
l
l
o
w
e
d
b
y
T
w
o
r
a
n
d
o
m
i
z
e
d
c
r
o
s
s
-
o
v
e
r
p
e
r
i
o
d
s
;
a
l
l
i
s
o
c
a
l
o
r
i
c
d
i
e
t
s
:
3
8
%
E
f
a
t
a
n
d
4
7
%
E
C
H
O
i
n
t
h
e
t
w
o
h
i
g
h
-
f
a
t
d
i
e
t
s
,
w
i
t
h
2
0
%
E
f
r
o
m
S
F
A
o
r
2
2
%
E
f
r
o
m
M
U
F
A
,
a
n
d
2
8
%
E
f
a
t
a
n
d
5
7
%
E
C
H
O
i
n
t
h
e
l
o
w
-
f
a
t
d
i
e
t
(
t
h
e
l
a
t
t
e
r
a
s
a
r
e
p
l
a
c
e
m
e
n
t
o
f
S
F
A
)
S
F
A
v
e
r
s
u
s
M
U
F
A
:
:
f
a
s
t
i
n
g
i
n
s
u
l
i
n
b
y
1
3
4
%
,
:
f
a
s
t
i
n
g
f
r
e
e
f
a
t
t
y
a
c
i
d
s
b
y
4
0
.
5
%
,
:
m
e
a
n
s
t
e
a
d
y
-
s
t
a
t
e
p
l
a
s
m
a
g
l
u
c
o
s
e
b
y
2
1
.
9
%
,
;
i
n
v
i
t
r
o
b
a
s
a
l
g
l
u
c
o
s
e
u
p
t
a
k
e
b
y
6
1
.
3
%
,
a
n
d
;
i
n
v
i
t
r
o
i
n
s
u
l
i
n
-
s
t
i
m
u
l
a
t
e
d
g
l
u
c
o
s
e
u
p
t
a
k
e
b
y
5
5
.
3
%
(
P
\
0
.
0
0
1
f
o
r
e
a
c
h
)
S
F
A
v
e
r
s
u
s
C
H
O
:
:
f
a
s
t
i
n
g
i
n
s
u
l
i
n
b
y
1
1
9
.
7
%
,
:
f
a
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123association between SFA intake and CHD risk. Comparing
the highest to the lowest category of consumption, the
pooled RRs in these two meta-analyses were 1.06 (95%
CI = 0.96–1.15) and 1.07 (95% CI = 0.96–1.19), respec-
tively. These meta-analyses suggest no overall effect of
SFA consumption on CHD events. However, these studies
were unable to separately evaluate whether consuming
SFA might have different effects on CHD events depend-
ing on the nutrient replaced, as would be suggested by
differing effects of SFA, depending on the comparison
nutrient, on blood lipids and apolipoproteins (Fig. 2).
The best observational evidence to-date of this question
is a recent pooled analysis of individual-level data from 11
prospective cohort studies across three continents, includ-
ing 344,696 individuals with 5,249 CHD events over
4–10 years of follow-up [69]. In fully multivariable-
adjusted analyses, SFA consumption was associated with
higher CHD risk only in comparison to PUFA. In other
words, only consumption of PUFA in place of SFA was
associated with lower CHD risk, whereas in fact con-
sumption of CHO or MUFA in place of SFA was associ-
ated with higher CHD risk or trends toward higher CHD
risk (Fig. 5). These associations were similar when analy-
ses were restricted to CHD deaths only, and were not
different in subgroups stratiﬁed by either sex or age.
Coronary Heart Disease—Randomized Controlled
Trials
Eight RCTs have investigated the effects of consuming
PUFA (either total or linoleic acid, LA) in place of SFA on
CHD events [70–77]. Most of these trials individually
found no signiﬁcant effects. A recent meta-analysis of
these RCTs, including a total of 13,614 participants with
1,042 CHD events, found that CHD risk was lowered by
10% for each 5%E greater PUFA intake replacing SFA
[78] (Fig. 5). Many of these trials have important limita-
tions, including for example not being double-blind;
incompletely assessing compliance; randomizing sites
rather than individuals and having open enrollment and
drop-out; and/or including vegetable oils that contained
omega-3 PUFA of plant origin that may provide cardio-
vascular beneﬁts unrelated to decreased SFA intake.
Nonetheless, the overall ﬁndings from these RCTs of CHD
endpoints are consistent with the results from prospective
cohorts (Fig. 5).
One large RCT has tested the effect of reducing SFA
consumption, replaced largely with CHO, on CHD events.
As described, the Women’s Health Initiative trial random-
ized 46,558 women to lower total fat consumption, that
included lowering of SFA consumption by *3%E over
8 years, and largely replaced with CHO. Even though this
was an unbalanced intervention (i.e., the intervention group
received extensive dietary counseling, whereas the control
group received usual care) that would generally bias toward
risk-reduction in the intervention group, there were no
signiﬁcant effects on either incident CHD (RR = 0.93,
95%CI = 0.83–1.05) or total CVD (RR = 0.96, 95%CI =
0.89–1.03) [79]. This absence of beneﬁt for substituting
SFA with CHO is consistent with expected effects based on
lipid changes (TC:HDL ratio) or observed relationships in
prospective cohort studies (Fig. 5).
Stroke: Prospective Cohorts and Randomized
Controlled Trials
Among ﬁve prospective cohort studies evaluating SFA
consumption and incidence of stroke, one of three found
n, cases % Weight RR (95% CI) Study
Overall estimate - Cohorts 0.98  (0.87, 1.10)
1.04  (0.62, 1.73)
1.03  (0.67, 1.59)
0.97  (0.78, 1.20)
0.95  (0.77, 1.18)
0.99  (0.81, 1.20)
100.00
4.92
6.87
27.48
27.48
33.25
1 .7 1.5
Meyer (2001)
55 , women
Salmeron(2001)53, women
van Dam (2002)54, men
Harding (2004)56, men 
Harding (2004)56, women
35988, 1890
84204, 2507
42504, 1321
9611, 198
11861, 143
1.05 (0.97, 1.11) Women's Health Initiative 45887, 1297
184168, 6059
Relative Risk of Incident Diabetes for High vs. Low Quantile of SFA Intake
Fig. 4 Relative risk of incident
diabetes associated with
consumption of saturated fat
(SFA). Multivariable-adjusted
results from prospective cohort
studies and the overall pooled
result using ﬁxed-effects meta-
analysis are shown. Results
from the Women’s Health
Initiative randomized controlled
trial are also shown comparing
controls (higher SFA intake) to
the intervention group in which
SFA was reduced by *3.2%E
over 8 years [79]. CI’s for
Harding et al.[56] were
estimated based on the numbers
of cases
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123SFA to be associated with lower risk of ischemic stroke
[80–82], and one of three found SFA to be associated with
lower risk of hemorrhagic stroke [80, 83, 84]. Four pro-
spective cohorts have also observed protective associations
between animal protein intake, that is often consumed
together with SFA, and risk of hemorrhagic stroke [85]. A
recent systematic review and meta-analysis of eight pro-
spective cohorts also found that SFA consumption was
associated with trends toward lower risk of stroke: com-
paring the highest to the lowest category of SFA intake, the
RR was 0.81 (95% CI = 0.62–1.05) [68]. In the Women’s
Health Initiative trial, reduction in SFA consumption did
not have a signiﬁcant effect on incident stroke over 8 years
(RR = 1.02, 95% CI = 0.90–1.17) [79]. Thus, overall,
SFA consumption does not appear to increase the risk of
stroke, and in fact some studies suggest a protective effect.
Further investigation of these effects, including indepen-
dence from potential beneﬁts of animal protein intake, is
warranted.
Future Research Directions
The multiple well-designed studies reviewed herein pro-
vide substantial evidence for health effects of SFA
consumption. However, important questions remain.
Although replacement of SFA with CHO appears to pro-
vide no overall CVD beneﬁt, indirect lines of evidence
suggest that effects could vary depending on overall CHO
quality [86–88]. For example, replacing SFA with less
processed, higher ﬁber, lower glycemic index CHO could
provide beneﬁt, whereas replacing SFA with more pro-
cessed, lower ﬁber, higher glycemic index CHO might
have no effects or even be harmful. Effects of replacing
SFA with CHO could also vary with an individual’s sus-
ceptibility to insulin resistance/metabolic syndrome, in
whom adverse metabolic effects of highly reﬁned CHO
may be more pronounced. Evidence for effects of replacing
SFA with MUFA is mixed. Such effects could vary
depending on other constituents in MUFA-containing
foods (e.g., animal fats vs. vegetable oils), for example due
to potentially beneﬁcial phytochemicals and ﬂavanols
contained in the latter but not the former. Each of these
issues requires direct investigation. Additionally, whereas
the substantial differences in blood lipid effects of different
chain-length SFA are clear, blood lipids represent only one
set of intermediate risk markers. Investigation of the effects
of different chain-length SFA on other risk pathways and,
more importantly, on disease endpoints is urgently needed
to determine the extent to which dietary and policy
Carbohydrate Replacing Saturated Fat
0.90 (0.83, 0.97)
RR (95% CI)
0.7 1.0 1.5
Relative Risk of Coronary Heart Disease for Each 5% Energy Intake
Results from Women's Health Initiative RCT 0.98 (0.88, 1.09)
Polyunsaturated Fat Replacing Saturated Fat
Meta-Analysis of 8 RCTs
Monounsaturated Fat Replacing Saturated Fat
0.91 (0.87, 0.95) Predicted Effect from TC:HDL Change
0.87 (0.77, 0.97) Pooled Analysis of 11 Observational Cohorts
Predicted Effect from TC:HDL Change 1.01 (0.98, 1.04)
Pooled Analysis of 11 Observational Cohorts 1.07 (1.01, 1.14)
RCTs – None --
Predicted Effect from TC:HDL Change 0.93 (0.89, 0.96)
Pooled Analysis of 11 Observational Cohorts 1.19 (1.00, 1.42)
Dietary Change (each 5% energy)
Fig. 5 Effects on coronary heart disease (CHD) risk of consuming
polyunsaturated fat (PUFA), carbohydrate (CHO), or monounsatu-
rated fat (MUFA) in place of saturated fat (SFA). Predicted effects are
based on changes in the TC:HDL-C ratio in short-term trials [5],
coupled with observed associations between the TC:HDL-C ratio and
CHD disease events in middle-aged adults [91]. Evidence for effects
of dietary macronutrients on actual CHD events comes from a meta-
analysis of eight randomized controlled trials (RCTs) for PUFA
replacing SFA, including 13,614 participants with 1,042 CHD events
[78]; and from the Women’s Health Initiative (WHI) RCT for CHO
replacing SFA, including 46,558 individuals with 1,185 CHD events
and *3.2%E reduction in SFA over 8 years [79]. Evidence for
observed relationships of usual dietary habits with CHD events comes
from a pooled analysis of 11 prospective cohort studies, including
344,696 individuals with 5,249 CHD events [69]. Reproduced with
permission from Mozaffarian et al., in press [78]
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123recommendations should focus on speciﬁc SFA rather than
overall SFA consumption. Additional investigation of
effects of SFA consumption on blood pressure, endothelial
function, insulin resistance, diabetes, and stroke (plus
stroke subtypes) is also needed, including consideration of
potential variation depending on both the replacement
nutrients and speciﬁc chain-length SFA under consider-
ation. Future research should also evaluate the health
effects of speciﬁc foods consumed, i.e., SFA intake from
different meats versus dairy versus tropical fats, as well as
how individual factors, such as age, sex, lifestyle factors,
predisposition to insulin resistance, or genetic variation,
may alter such responses.
Conclusions
Current public health dietary recommendations often pri-
oritizethereductionofSFAconsumptiontopreventCVD.A
review of the current evidence, particularly ﬁndings from
well-performed RCTs of risk pathways, large prospective
cohortsofdiseaseendpoints,andRCTsofdiseaseendpoints,
suggests that this focus may not produce the intended ben-
eﬁts. First of all, substantial evidence indicates that health
effects of reducing SFA vary depending on the replacement
nutrient. Based on the best evidence from human studies,
replacing SFA with PUFA (e.g., vegetables, vegetable oils)
lowers CHD risk, whereas replacing SFA with CHO has no
beneﬁts. Replacing SFA with MUFA has uncertain effects,
based on mixed evidence within and across different
research paradigms. Of note, the effects of replacing SFA
with PUFA or CHO, but not MUFA, on clinical CHD end-
points could be relatively predicted from the effects of these
nutrientsubstitutions ontheTC:HDL-C ratio. Thus,policies
that prioritize the reduction of SFA consumption without
speciﬁcally considering the replacement nutrient may have
little or no effects on disease risk, especially as the most
common replacement in populations is often CHO.
Second, even under optimal replacement scenarios of
SFA for PUFA, the magnitude of likely beneﬁt warrants
attention. RCTs of the blood TC:HDL-C ratio, prospective
cohorts of disease endpoints, and RCTs of disease end-
points each converge on *10% reduction in CHD events
for 5%E substitution of SFA with PUFA. This approaches
the maximal plausible risk reduction in most populations;
in the US, for example, such beneﬁt would require overall
population decrease from the current 11.5 to 6.5%E SFA
consumption. Thus, although recommendations to replace
SFA with PUFA appear appropriate, the much larger CVD
burdens caused by other dietary factors (e.g., low omega-3,
low fruits and vegetables, high trans fat, and high salt) [89]
appear to warrant much more attention. Finally, although
investigation of individual nutrients provides important
information on potential underlying mechanisms of health
effects, people make decisions about eating whole foods
that contain multiple macro- and micronutrients in various
amounts. Thus, food-based scientiﬁc research and policy
recommendations may be most relevant in the modern era
to understand and reduce the pandemics of chronic disease
occurring in nearly all nations.
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